Rakovina Therapeutics partners with Celvion to apply AI to ATR inhibitor development

• Rakovina Therapeutics entered a research collaboration with Boston-based Celvion Therapeutics to support its ATR inhibitor program.
• Celvion’s EMphora AI platform will analyze real-world clinical outcomes data to identify precision targets, combinations, biomarkers, patient subgroups.
• Work aims to generate clinically actionable hypotheses to guide biomarker-driven patient selection, combination-study priorities, clinical development design.
• Parties may pursue co-development or economic arrangements if the analysis identifies promising development opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rakovina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010530PRIMZONEFULLFEED9837551) on October 01, 2026, and is solely responsible for the information contained therein.